CMPX

Compass Therapeutics, Inc.

Fundamental data last updated:November 17, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

03/04/2027

Business Summary

Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.

 


VALUATION

P/E

-1.77

Market Cap ($M USD)

$148.45M

Forward P/E

3.63

PEG

-0.08

PRICE TO SALES

0.00

PRICE TO BOOK

1.08

EV / EBITDA

-1.37

5-Year Average P/E

Free Cash Flow Yield

-40.84%

DCF Value

$0.12

Graham Number

N/A

Price to FCF

-2.45

EV to FCF

-1.92

Earnings Yield

-56.08%

FCF Yield

-40.84%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.46

Next Year EPS Growth Estimate

-$0.52

Next Year Revenue Growth Estimate

$39.32M

Return on Equity (ROE)

-49.93%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.06

Piotroski F-Score

1

Altman Z-Score

-1.85

Return on Invested Capital (ROIC)

-61.97%

Current Ratio

6.79

Quick Ratio

6.79

Net Debt to EBITDA

0.38

Interest Coverage

0.00

Gross Profit margin

0.00%

FCF PER SHARE

$-0.32

REVENUE PER SHARE

$0.00

Gainseekers Quantitative Analysis

Summary

CMPX’s valuation paints a stark picture of market skepticism. With a Forward P/E of 3.63, the market anticipates some future profitability, yet the negative Earnings Yield and Altman Z-score of -0.29 signal distress. The stock’s price has been trading significantly below its DCF value, suggesting potential undervaluation. However, the negative ROIC and a Piotroski F-Score of 3 raise red flags about operational inefficiencies and financial health. This is a speculative play, with the market pricing in substantial risk.

AI Exposure / Tech Reliance

In the biotechnology sector, CMPX is well-positioned to leverage AI advancements for drug discovery and development. The industry's inherent need for innovation aligns with AI's capabilities to enhance research efficiency. However, execution will be key in translating tech potential into tangible results.

The Bull Case

For the bullish investor, CMPX offers a compelling narrative of potential turnaround. Despite a negative ROIC, the company's low Debt/Equity ratio of 0.058 suggests financial prudence. The high Current Ratio of 11.22 indicates robust liquidity, providing a cushion for strategic pivots. With a consensus "Buy" rating, there's institutional confidence in its long-term prospects, despite current operational challenges.

The Bear Case

The bear case for CMPX is glaringly evident in its financial metrics. The negative EPS and FCF Yield highlight a company struggling to generate cash flow. With an EV to EBITDA of -1.56, profitability remains elusive. The stock's significant distance from its 52-week high suggests market pessimism, compounded by a dismal Altman Z-score indicating potential financial distress.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$4.67

Institutional Ownership %

1-Year Beta

0.91

Insider Buying % (6 Mo)

Distance to 52-Week High

734.65%

Distance to 52-Week Low

18.60%

EARNINGS SURPRISE %

-18.70%

50-DAY SMA

$1.23

200-DAY SMA

$3.01

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.